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Objective. To issue guidelines for the care of acute stroke in Hong Kong, with
the target audience of all health care professionals who are involved in acute
stroke care.
Participants. The Hong Kong Neurological Society and the Hong Kong Stroke
Society.
Evidence. The panel applied the ‘rule of evidence’ used by the United States
Agency for Health Care Policy and Research. When there is insufficient evidence,
the recommendation was based on customary practice and was circulated among
the members and fellows of the two societies before coming to a consensus.
Consensus process. Group meetings were held in 2002 to review the literature
about acute care for patients with ischaemic stroke and to issue a consensus
statement with reference to the local health care system. Participants of the meet-
ings were appointed by the councils of The Hong Kong Neurological Society
and the Hong Kong Stroke Society. The draft statement was circulated among
the members and fellows of the two societies for comments before it was finalised.
Conclusions. Ischaemic stroke is a heavy health care burden to Hong Kong. The
current consensus statement provides a framework to establish a multidisciplinary
approach towards its acute management.
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Introduction
Stroke is the second most common cause of mortality worldwide and is the ma-
jor cause of permanent disability. In Hong Kong, despite a drop in the standard-
ised mortality rate from 8.72 per 1000 in 1961 to 4.05 per 1000 in 2000, the total
stroke mortality remained high because of the ageing population. For example,
in 2001, there were 3130 deaths from stroke, accounting for 9.4% of all deaths in
Hong Kong.1
Stroke is a heterogeneous condition, and the care of each patient should be
tailored to the individual’s needs. These guidelines focus only on ischaemic stroke,
which is responsible for more than 70% of the local incidence of stroke. Al-
though the management of haemorrhagic stroke requires a different treatment
strategy, some of the principles of patient care still apply. The guidelines are
based on current evidence2-4 available in the following areas: organisation of
stroke services, assessment for the patients with acute stroke, treatment for acute
ischaemic stroke, and strategies for secondary prevention. The evidence ratings
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used are shown in the Table and, where appropriate, in
parentheses below.
(A) Organisation of stroke services
The stroke unit is an essential part of an organised stroke
service. Admission and management of patients with stroke
into an acute stroke unit have been proven to save lives,
increase the number of independent survivors, and reduce
institutionalisation among survivors in a cost-effective
manner (level Ia).5-7 All patients with a clinical diagnosis
of stroke should be triaged at the accident and emergency
department and admitted to an acute stroke unit to receive
rapid investigation and treatment. For patients with tran-
sient ischaemic attack (TIA), rapid referral to a specialised
clinic with a concerted programme and relevant investiga-
tions (eg blood tests, computed tomography [CT] of the
brain, and Doppler studies) is recommended (level IV).8
The acute stroke unit should comprise the following:
• A geographically identified unit to provide adequate
in-patient service to patients with acute stroke;
• A coordinated multidisciplinary team;
• Staff with specialist expertise and interest in stroke care;
• An agreed integrated pathway or protocol for acute
stroke care that allows flexibility to address any unique
conditions of individual patients;
• An education programme for professionals, patients,
and their carers;
• Regular audit to achieve the best model of stroke care
practice; and
• Integration with the community and domiciliary reha-
bilitation programme to facilitate patients returning
home.
Recommendations
• Patients with acute stroke should be admitted to a des-
ignated acute stroke unit that has a multidisciplinary
stroke service under the leadership of a stroke specialist.
• Patients with TIAs should be referred for fast-track
assessment in a specialised clinic for early evaluation
and intervention.
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Table. Ratings used to classify evidence about stroke care (B) Acute assessment
For all patients with stroke, multidisciplinary assess-
ments should be made as soon as possible to achieve the
following:
• To confirm the diagnosis of stroke;
• To define the pathology of stroke and the site of
involvement;
• To assess the functional impairment and avoid
complications;
• To recognise the disabilities and allow prediction of
the prognosis; and
• To identify the underlying risk factors (Box 1) and
determine the strategies for secondary prevention.
The following points should be considered when deciding
which assessments are needed:
(1) Clinical scoring systems are unreliable in differentiat-
ing cerebral haemorrhage or infarction. The findings
from CT of the brain are important in guiding therapy
for acute stroke, and all patients with acute stroke
should have a CT scan of the brain performed as soon
as possible (preferably within 24 hours of presentation).
The requirement for an emergency CT study (within
3-4 hours, and the sooner the better) is indicated in the
following situations:
• Clinical suspicion of subarachnoid haemorrhage or
a traumatic cause;
• Depressed consciousness;
• Doubtful diagnosis because of other atypical
features;
• Suspected or known bleeding tendency;
• Unexplained progressive or fluctuating symptoms;
and
• Consideration of thrombolytic therapy.
(2) Magnetic resonance imaging (MRI) is more sensitive
than CT in the detection of small infarctions or brain
stem lesions, but it is more expensive and less widely
available.
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Box 1. Risk factors for ischaemic stroke
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(3) The use of a clinical stroke score, such as the National
Institutes of Health Stroke Score, is helpful in assess-
ing the impairment of patients and may be useful in
the prediction of the prognosis.
(4) All patients with acute stroke should be examined for
swallowing difficulty by trained staff, and dysphagic
patients should be referred to a speech therapist for
further management.
(5) All patients with acute stroke should be assessed
by nursing staff and allied professionals (eg a physio-
therapist, occupational therapist, and speech therapist)
to identify the degree of social, psychological, and
physical disability, thereby allowing triage into differ-
ent rehabilitation programmes.
(6) All patients with stroke should be tested for their com-
plete blood picture, coagulation profile (international
normalised ratio [INR], activated partial thromboplas-
tin time), serum levels of urea and electrolytes, ran-
dom and fasting blood glucose levels, and fasting lipid
level; they should also have a chest X-ray and electro-
cardiogram performed. Close monitoring of the
patient’s level of consciousness, vital signs, and
neurological condition is important for the early
detection of clinical deterioration and complications.
Suitable patients should undergo carotid duplex and
transcranial Doppler examinations. Additional
investigations (eg screening for hypercoagulable
states, bleeding diatheses, transthoracic or transoeso-
phageal echocardiography, and MRI) should be con-
sidered for selected patients.
Recommendations
• All patients with acute stroke should receive full medi-
cal assessment and other multidisciplinary assessments
as soon as possible.
• In addition to routine investigations, the clinical con-
dition may warrant more specialised investigations.
• Computed tomography of the brain should be per-
formed for all patients with acute stroke within 24 hours
of presentation, or sooner if indicated.
(C) Acute treatment
The following is a summary of the current evidence for vari-
ous treatments modalities:
(1) Aspirin treatment has been proven to have a small ben-
efit in reducing the death and recurrent stroke rate—
namely, it results in a net decrease of 9 (standard
deviation, 3) deaths or occurrences of further stroke
per 1000 patients (level Ia).9-11 For example, the CAST
(Chinese Acute Stroke Trial) study confirmed the
benefit of aspirin therapy among Chinese patients
with acute ischaemic stroke. Aspirin at a dosage of
75 mg to 325 mg daily should be started within 48
hours of the onset of stroke but only after the exclu-
sion of intracranial bleeding and when there are no
other contra-indications. There has so far been no
evidence that other antiplatelet agents have similar
benefits in treating acute ischaemic stroke.
(2) The use of recombinant tissue plasminogen activator
as thrombolytic therapy has been shown by the NINDS
(National Institute of Neurological Disorders and
Stroke) study to be beneficial in highly selected pa-
tients within 3 hours of onset of acute ischaemic stroke
(level Ib).12 Strict adherence to the selection criteria is
critical, however, to ensure a good outcome.13 Throm-
bolytic therapy may cause catastrophic cerebral
haemorrhage, which raises local concern because
haemorrhagic stroke is much more prevalent among
the Chinese population than among Caucasians. Hence,
thrombolytic therapy for Chinese patients with acute
ischaemic stroke should be carried out only as part of a
strictly controlled and monitored protocol by stroke
specialists until either the safety of its use in Chinese
patients is proven or the health delivery system can
facilitate early identification of appropriate candidates.
(3) Low-molecular-weight (LMW) heparin as anticoagu-
lation therapy within 48 hours of the onset of stroke
has been shown by the FISS (Fraxiparine in Ischaemic
Stroke) study to result in a significant improvement in
6 month’s outcome among local patients with cerebral
infarction (level Ib).14 This result, however, could not
be reproduced in other studies.15,16 The FISS-Tris study,
a multicentre trial, is currently ongoing in Hong Kong
and Singapore, and the results will clarify the role of
LMW heparin in treating Asian patients with acute
cerebral infarction. The use of anticoagulation therapy
in patients with acute ischaemic stroke plus atrial
fibrillation has not been shown to be better than
aspirin therapy.17
(4) Although nimodipine is used in patients with subarach-
noid haemorrhage to lessen ischaemic complications,
its effectiveness has not been proven in treating acute
cerebral infarction. Clinical trials involving several
neuroprotective agents have failed to reproduce the
positive outcomes seen in experimental studies.18
No neuroprotectant is currently available for acute
ischaemic stroke.
(5) High blood pressure is common after cerebral infarc-
tion and often settles down gradually with conserva-
tive treatment. The rapid lowering of a patient’s blood
pressure in the acute phase of stroke may be detri-
mental. The blood pressure should not be lowered
unless the systolic blood pressure is 220 mm Hg or
higher, or the diastolic blood pressure is 120 mm Hg
or higher, according to repeated measurements taken
20 minutes apart; or unless there are associated hyper-
tensive emergencies, dissecting aortic aneurysm,
encephalopathy, or heart failure.
(6) Fever and hyperglycaemia may lead to a poor outcome
for patients with stroke, and their causes should be
sought and treated accordingly. Fever may be lowered
with paracetamol.
(7) Neurosurgical intervention may be considered in se-
lected patients, such as those with large infarctions and
mass effects (with midline shift or compression of the
basal cisterns) or hydrocephalus.
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Recommendations
• Aspirin (75-325 mg/d) should be started within 48
hours of the onset of stroke and after intracranial bleed-
ing and other contra-indications have been excluded.
• Anticoagulation treatment should not be considered
as standard treatment until further clinical data are
available for the local population.
• Thrombolytic therapy should not be considered as
standard treatment until its safety for use in the local
population has been shown.
• High blood pressure in the acute phase of disease
should not be actively lowered unless there is a hyper-
tensive emergency.
• Hyperglycaemia (blood glucose level >10 mmol/L),
dehydration, pyrexia (and its cause) should be treated
actively.
• Neurosurgical interventions may be considered in se-
lected patients.
(D) Secondary prevention
The annual stroke recurrence rate ranges from about 5%
to 10%, and patients with recurrent stroke also carry an
increased risk of myocardial infarction and other vascular
events. Appropriate use of antithrombotic agents can
reduce the risk of recurrent ischaemic stroke and is
associated with an acceptable risk of complications. Major
risk factors (Box 1) should be controlled aggressively
as follows:
(1) Patients with ischaemic stroke who experience atrial
fibrillation (valvular or non-valvular) should be given
anticoagulation therapy unless contra-indicated.19 War-
farin is expected to reduce the risk of a further ischae-
mic stroke to the same extent as primary prevention.
The INR level should be kept between 2.0 and 3.0 (and
higher for prosthetic valves); however, whether this
INR range is also optimal for the Asian population
remains to be proven. Patients who are not suitable
for anticoagulation should be considered for aspirin
prophylaxis.
(2) Aspirin therapy after an ischaemic stroke can reduce
the risk of serious vascular events by one fourth. Low-
dose aspirin (75-325 mg/d) is at least as effective as
higher-dose treatment and causes fewer gastrointest-
inal side-effects.20 The absolute reduction in the risk
was 36 (standard error, 6) cases per 1000 patients
treated for 2 years among those with previous stroke
or TIA. Other antiplatelet agents may have some
additional effects but are much more expensive
and should not be considered as first-line treatments.
(3) The prevalence of carotid stenosis among the local
population is lower than that among Caucasians; sig-
nificant intracranial stenosis is more common in the
Chinese population. Suitable candidates (with symp-
tomatic moderate or severe carotid stenosis of >50%
to 99%) should be referred to carotid surgery centres
that have suitable experience and expertise in carotid
endarterectomy. Carotid angioplasty with stenting is a
new mode of intervention currently under evaluation,
and it is not a standard treatment until further clinical
data are available.
(4) Control of blood pressure lowers the risk of first
or recurrent stroke. This is true for various forms of
hypertension and across different age-groups. It may
also hold true in patients who have a blood pressure
within the normal range. The blood pressure should
be kept below 130/85 mm Hg. However, there is
no lower threshold for the benefit of blood pressure
treatment regarding stroke prevention. Recent
studies have indicated that angiotensin-converting
enzyme inhibitors may offer additional advantages
other than the lowering of blood pressure.21,22
(5) Diabetes mellitus is a major vascular risk factor, and
the blood glucose level needs to be controlled aggres-
sively with dietary restriction, oral hypoglycaemic
agents, or insulin. The Heart Protection Study23 has
demonstrated the benefit of lipid-lowering therapy
among patients with ischaemic stroke, and aggressive
lowering of lipid levels is recommended. All patients
should be advised to adopt a healthy lifestyle (such as
stopping smoking, maintaining an optimal body mass
index of <23, exercising regularly, and having a low
salt intake).
Recommendations
• Aspirin therapy should be started as soon as possible
for the secondary prevention of recurrent ischaemic
stroke and other vascular risk events.
• Anticoagulation should be considered for cardio-
embolic stroke if this is not contra-indicated.
• Suitable candidates should be identified and referred
to experienced carotid surgery centres for considera-
tion of carotid endarterectomy.
• Hypertension, diabetes mellitus, and hypercholestero-
laemia should be controlled, and every patient should
be strongly encouraged to stop smoking and adopt a
healthy lifestyle.
The summary of the guidelines for the care of acute stroke
is shown in Box 2.
Conclusion
Improving the quality of stroke care can be achieved by re-
organising services as follows:
• Set up a geographically designated acute stroke unit;
• Create an effective multidisciplinary team;
• Reorganise the health delivery system to facilitate
patient-oriented service;
• Provide training for staff; and
• Enhance good collaboration among various specialties
and the community health system.
This consensus statement focuses on the acute-phase
management of ischaemic stroke, but other important
areas in stroke services, such as primary stroke preven-
Ng et al
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(b)
tion, rehabilitation, and community services, should not
be ignored. Recent studies have pointed to the efficacy
of stroke rehabilitation in altering outcomes and the
overall durability of gains from rehabilitation. Rehabili-
tation should commence as soon as the patient’s medical
and neurological conditions permit, and should be formu-
lated according to the individual’s need. The compre-
hensive care of patients with stroke requires concerted
efforts from all aspects of health care. Strategies should be
developed to promote education at the levels of health care
providers and community to improve the various aspects
of stroke care.
New evidence about stroke care is emerging at a fast
pace, and current consensus statement should be reviewed
regularly to update the evidence-based approaches to stroke
management.
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